Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Lenalidomide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention. Browse Lenalidomide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 7:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
703
Shown on this page
12
Current sort
Recently updated
Therapy scope
Lenalidomide
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Lenalidomide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 361–372 of 703 matching trials for Lenalidomide.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)

NCT03645395
View directory record Official record
Conditions
Non-hodgkin Lymphoma
Interventions
MT-3724
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years to 101 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Whittier, California • Plantation, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Terminated Phase 2 Interventional Results available

Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL

NCT01241786
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma
Interventions
Revlimid, Azacitidine
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Phase 1 Interventional

Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome

NCT03113695
View directory record Official record
Conditions
Richter's Syndrome, CLL
Interventions
Obinutuzumab, lenalidomide, HDMP
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

NCT01239797
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63)
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
63
States / cities
Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Terminated Phase 1 Interventional

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

NCT01744912
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-cell Lymphomas, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Ublituximab, Lenalidomide
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Huntsville, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Phase 2 Interventional Results available

Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

NCT01463670
View directory record Official record
Conditions
Multiple Myeloma
Interventions
lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Stamford, Connecticut • Basking Ridge, New Jersey • Brooklyn, New York + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

NCT02631577
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Atezolizumab (MPDL3280A) [TECENTRIQ], Lenalidomide, Obinutuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Miami, Florida • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Phase 1 Interventional

Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

NCT01433965
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Lenalidomide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Not applicable Interventional

Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone

NCT03375567
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Guided Lesion Biopsies, Standard Lesion Biopsies
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Phase 1 Interventional

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

NCT01583283
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215, lenalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
5
States / cities
Boston, Massachusetts • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Terminated Phase 1 Interventional Results available

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

NCT02954406
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
TAK-659, Bendamustine, Rituximab, Gemcitabine, Lenalidomide, Ibrutinib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 28, 2026, 7:40 AM EDT
Completed Phase 1 Interventional

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02086604
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Brentuximab vedotin, Lenalidomide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Oct 28, 2026, 7:40 AM EDT

About this Lenalidomide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Lenalidomide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lenalidomide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Lenalidomide.